Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension study of enzalutamide in prostate cancer
NL-OMON58726Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoint: Long-term safety. Started Mar 2023; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON58726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58726.